【制药网 行业动态】8月1日,赛诺菲宣布与 Arrowhead 的子公司维亚臻(Visirna Therapeutics)签署资产购买协议。根据协议,赛诺菲将获得在大中华区开发和商业化在研药物普乐司兰钠注射液(Plozasiran)的权利。资料显示,普乐司兰钠,是一种在研RNA干扰(RNAi)疗法,旨在减少载脂蛋白 C-III(APOC3)的生成,从而降低甘油三酯水平,并将脂质恢复到更正常的水平。...
Source Link【制药网 行业动态】8月1日,赛诺菲宣布与 Arrowhead 的子公司维亚臻(Visirna Therapeutics)签署资产购买协议。根据协议,赛诺菲将获得在大中华区开发和商业化在研药物普乐司兰钠注射液(Plozasiran)的权利。资料显示,普乐司兰钠,是一种在研RNA干扰(RNAi)疗法,旨在减少载脂蛋白 C-III(APOC3)的生成,从而降低甘油三酯水平,并将脂质恢复到更正常的水平。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.